NORWELL, Mass. — In a significant step toward addressing the persistent talent and knowledge gap in biomedical exploration, the National Organization for Rare Disorders (NORD®) and the Rosenau Family Research Foundation officially launched a comprehensive, free educational initiative aimed at inspiring and training the future workforce of medical science. Titled the "Rare Research Launchpad: A Career Exploration Series in Rare Disease Research," the newly introduced online program is designed specifically to introduce students, trainees, and early-career scientists to the intricate world of rare disease research and the diverse professional pathways available within the field.
The self-paced learning series, made available through NORD’s established RareEDU® online learning platform, seeks to bridge the gap between academic interest and practical application. By leveraging real-world case studies centered on cystic fibrosis and Krabbe disease, the curriculum guides participants through the foundational science of rare disorders. It meticulously illustrates how scientific discoveries transition from initial laboratory investigations toward the painstaking development of potential life-changing therapies. Furthermore, the program sheds light on the multifaceted skills, multidisciplinary experiences, and specialized career pathways required to successfully advance rare disease research in modern medical environments.
Funded generously by the Rosenau Family Research Foundation—a dedicated NORD Member Organization—and meticulously developed by NORD in collaboration with expert researchers from the esteemed NORD® Rare Disease Centers of Excellence Network, the launchpad represents a collaborative milestone in educational outreach. The initiative uniquely combines rigorous scientific learning with deeply personal perspectives from academic researchers and families directly affected by rare conditions. Alongside these narratives, the curriculum provides practical career guidance, making it an invaluable asset for students interested in science, medicine, and public health who may otherwise have had limited exposure to rare disease research or awareness of the career opportunities thriving within the specialty. Additionally, the series serves as a robust supplemental resource for advanced graduate students and early-career medical trainees looking to focus their professional trajectories on specialized biomedical domains.
The genesis of this educational platform addresses a critical and growing need within the scientific community. As modern technologies utilized to study complex rare and genetic diseases accelerate at an unprecedented pace, the demand for a specialized, highly prepared workforce has never been more urgent. Speaking on the launch of the initiative, Rebecca Aune, MPA, Director of Education Programs at NORD, emphasized the critical timing of the program. As technologies used to study rare and genetic diseases and develop new therapies continue to advance, she noted, the scientific community must actively prepare the next generation of researchers who will carry this vital work forward. The Rare Research Launchpad is structured to give students an early, comprehensive look at rare disease research, helping them understand the specific technical skills, collaborative relationships, and professional experiences that can pave the way toward a rewarding career dedicated to advancing science and improving the lives of millions of people affected by rare diseases.
The selection of cystic fibrosis and Krabbe disease as the foundational case studies for the launchpad was a deliberate choice, driven by the unique learning opportunities and scientific challenges they present. Together, these two conditions expose participating students and trainees to broad, essential principles spanning genetics, molecular biology, neuroscience, and advanced biomedical research. More importantly, the case studies demonstrate how foundational laboratory science, acute clinical expertise, and the lived experiences of patients and families can collectively inform research priorities and accelerate the development of innovative new treatments.
These two conditions also reflect different, illuminating points along the broader therapeutic development landscape, offering students a realistic view of medical research progress. Cystic fibrosis has notably benefited from decades of sustained, dedicated research that has successfully yielded multiple Food and Drug Administration-approved therapies, including precision treatments designed to target the underlying molecular disease process. In stark contrast, there is currently no FDA-approved therapy specifically indicated to treat Krabbe disease, highlighting an urgent, unmet medical need. By examining both conditions side-by-side, participants gain a balanced and unvarnished perspective on both the extraordinary progress that rare disease research can achieve through persistence and collaboration, and the formidable scientific and therapeutic challenges that still remain across the broader rare disease field.
The Rosenau Family Research Foundation brings a deeply personal and mission-driven perspective to the collaboration. Established to improve the outlook for those impacted by these specific conditions, the foundation’s leadership views educational investment as a cornerstone of future medical breakthroughs. Gabriel M. Cohn, MD, MBA, Executive Director and Medical Director of the Foundation, underscored the organization’s commitment to nurturing upcoming talent. The Rosenau Family Research Foundation is intensely focused on advancing research that can tangibly improve the lives of people affected by Krabbe disease and cystic fibrosis, Dr. Cohn explained. Supporting NORD’s Rare Research Launchpad allows the foundation to invest directly in future scientists while equipping them with a practical, grounded understanding of the intricate research questions, collaborative career paths, and cross-sector partnerships needed to advance treatments. This mission carries immense urgency when viewed against the broader epidemiological landscape, noting that there are more than 10,000 known rare diseases, of which only about 600 currently have an available, FDA-approved treatment.
Designed with scalability in mind, the Rare Research Launchpad is structured as a flexible model that has the capacity to expand over time. As the initiative grows, it will introduce participants to additional rare disease research topics, thereby widening the scope of study and providing even more avenues for student career exploration, mentorship, and professional engagement within the rare disease community.
The Rare Research Launchpad is currently live and accessible online at learn.rarediseases.org, with full participation offered entirely free of charge to interested students and trainees worldwide.
The National Organization for Rare Disorders, founded in 1983, operates as a prominent independent, nonpartisan nonprofit organization dedicated entirely to improving the health, well-being, and daily lives of the more than 30 million Americans who live with rare diseases. Working in active partnership with over 350 disease-specific member patient organizations and 49 designated NORD Rare Disease Centers of Excellence—which span more than 170 premier academic medical centers, specialized research institutions, and children’s hospitals nationwide—NORD continually advances comprehensive care, innovative research, targeted education, and robust public advocacy to foster a better future for every affected individual and family.
The Rosenau Family Research Foundation operates as a 501(c)(3) private family foundation established in 2008 with the explicit mandate to improve the lives of individuals and families impacted by Krabbe disease and cystic fibrosis through focused research funding and advocacy. The Foundation actively supports basic, translational, and clinical research initiatives, alongside comprehensive education and community awareness campaigns designed to advance novel treatments, potential cures, expanded newborn screening, and a deeper scientific understanding of both conditions.
